Protalix BioTherapeutics (PLX) Tops Q1 EPS by 40c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. SPY
8. AAPL
9. LITE
10. NVT

Go back to Protalix BioTherapeutics (PLX) Tops Q1 EPS by 40c, Revenues Beat

Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update

June 1, 2020 6:50 AM EDT

CARMIEL, Israel, June 1, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the first quarter ended March 31, 2020, and provided a business update on recent corporate and clinical developments. The Company's management will discuss the financial results and provide a clinical, corporate and financial highlights on a conference call and live webcast scheduled for Monday, June 1, 2020 at... More